Tamoxifen embedded in lipid bilayer improves the oncotarget of liposomal daunorubicin in vivo.

The objective of this research is to investigate the plasma pharmacokinetics and bio-distribution of liposomal daunorubicin plus tamoxifen in breast cancer murine models through intravenous administration. Daunorubicin and tamoxifen plasma levels in pharmacokinetics studies were determined using HPLC. Biodistributions of various carriers loaded with a cyanine dye (cy7) were evaluated using in vivo imaging. After administration, free daunorubicin and tamoxifen were rapidly cleared out from the blood following a two-compartment kinetic model. The clearances and AUC (0-∞) of daunorubicin were (means ± SD): 0.028 ± 0.005 L h-1 kg-1 and 367.489 ± 56.979 μg mL-1 h-1 (liposomes), and 2.235 ± 0.347 L h-1 kg-1 and 4.546 ± 0.704 μg mL-1 h-1 (free drug). By ex vivo imaging 24 h after injection, the fluorescence intensity of liposomal cy7 plus tamoxifen in tumor region was obviously higher than that of free liposomal cy7. In conclusion, tamoxifen can improve pharmacokinetics profile of liposomal daunorubicin with enhanced therapy for breast cancer.

[1]  Ming-hui Li,et al.  The liposomal daunorubicin plus tamoxifen: improving the stability, uptake, and biodistribution of carriers , 2012, Journal of liposome research.

[2]  Yuquan Wei,et al.  Therapeutic application of injectable thermosensitive hydrogel in preventing local breast cancer recurrence and improving incision wound healing in a mouse model. , 2012, Nanoscale.

[3]  F. DuBru,et al.  Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. , 1996, Molecular pharmacology.

[4]  R. Mumper,et al.  Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia. , 2009, Journal of biomedical nanotechnology.

[5]  R. Scheper,et al.  Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia , 2001, British journal of haematology.

[6]  Xin-Peng Zeng,et al.  Nanomaterials in cancer-therapy drug delivery system. , 2013, Journal of biomedical nanotechnology.

[7]  U. Persson,et al.  Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma. , 1999, Acta oncologica.

[8]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[9]  C. Peterson,et al.  Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance. , 2002, Cancer letters.

[10]  Yaping Li,et al.  Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism. , 2011, Nanoscale.

[11]  S. Veintemillas-Verdaguer,et al.  Biodistribution and pharmacokinetics of uniform magnetite nanoparticles chemically modified with polyethylene glycol. , 2013, Nanoscale.

[12]  N. Voelcker,et al.  Fabrication of self-supporting porous silicon membranes and tuning transport properties by surface functionalization. , 2010, Nanoscale.

[13]  Yan Zhang,et al.  Effects of stealth liposomal daunorubicin plus tamoxifen on the breast cancer and cancer stem cells. , 2010, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[14]  G. Szakács,et al.  Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties , 2009, British journal of pharmacology.

[15]  R. White,et al.  Biosynthesis of daunorubicin glycosides: role of epsilon-rhodomycinone , 1980, Antimicrobial Agents and Chemotherapy.

[16]  Zhe-Sheng Chen,et al.  Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. , 2009, Biochemical pharmacology.

[17]  Jie Meng,et al.  Inhibiting metastasis of breast cancer cells in vitro using gold nanorod-siRNA delivery system. , 2011, Nanoscale.

[18]  R. Kayyali,et al.  Tamoxifen decreases drug efflux from liposomes: Relevance to its ability to reverse multidrug resistance in cancer cells? , 1994, FEBS letters.

[19]  L. Wilkens,et al.  Comparative Epidemiology of Breast Cancer Among Men and Women in the US, 1996 to 2000 , 2006, Cancer Causes & Control.

[20]  Y. Barenholz,et al.  Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. , 1993, Biochimica et biophysica acta.

[21]  I V Zhigaltsev,et al.  LIPOSOMES CONTAINING DOPAMINE ENTRAPPED IN RESPONSE TO TRANSMEMBRANE AMMONIUM SULFATE GRADIENT AS CARRIER SYSTEM FOR DOPAMINE DELIVERY INTO THE BRAIN OF PARKINSONIAN MICE , 2001, Journal of liposome research.

[22]  Hongzhuo Liu,et al.  Efficacy and biodistribution of tocopheryl polyethylene glycol succinate noncovalent functionalized single walled nanotubes loading doxorubicin in sarcoma bearing mouse model. , 2012, Journal of biomedical nanotechnology.

[23]  V. Ling,et al.  Decreased P-glycoprotein in a tamoxifen-tolerant breast carcinoma model. , 1991, Anticancer research.

[24]  Pengfei Rong,et al.  VEGF-loaded graphene oxide as theranostics for multi-modality imaging-monitored targeting therapeutic angiogenesis of ischemic muscle. , 2013, Nanoscale.

[25]  B. Leyland-Jones,et al.  Sensitization to doxorubicin resistance in breast cancer cell lines by tamoxifen and megestrol acetate. , 1996, Biochemical pharmacology.

[26]  A. Garnier-Suillerot,et al.  Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P. , 2000, European journal of pharmacology.

[27]  G. Goldenberg,et al.  Anatagonism of the cytocidal activity and uptake of melphalan by tamoxifen in human breast cancer cells in vitro , 1985 .